Vir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment

Reuters

2025/07/31

<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a> Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment

Vir Biotechnology Inc. has announced the initiation of the ECLIPSE 2 Phase 3 clinical trial, part of its global ECLIPSE registrational program for chronic hepatitis delta $(CHD)$. The trial aims to evaluate the efficacy of combining tobevibart and elebsiran against continued bulevirtide monotherapy in patients with CHD who have not achieved undetectable levels of hepatitis delta virus $(HDV)$ RNA despite ongoing treatment with bulevirtide. ECLIPSE 2 is one of three trials in the program, designed to provide the necessary efficacy and safety data for potential submission to global regulatory agencies. This development follows compelling results from the Phase 2 SOLSTICE clinical trial, which demonstrated the potential of the investigational combination to reduce HDV to undetectable levels. The outcomes of ECLIPSE 2 will be presented in the future, pending the completion of the trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250731294819) on July 31, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2555838315"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555838315\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555838315?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555838315","market":"fut","top_or_hot":-1,"title":"Vir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. has announced the initiation of the ECLIPSE 2 Phase 3 clinical trial, part of its global ECLIPSE registrational program for chronic hepatitis delta <a href=\"https://laohu8.com/S/CHD\">$(CHD)$</a>. The trial aims to evaluate the efficacy of combining tobevibart and elebsiran against continued bulevirtide monotherapy in patients with CHD who have not achieved undetectable levels of hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> RNA despite ongoing treatment with bulevirtide. ECLIPSE 2 is one of three trials in the program, designed to provide the necessary efficacy and safety data for potential submission to global regulatory agencies. This development follows compelling results from the Phase 2 SOLSTICE clinical trial, which demonstrated the potential of the investigational combination to reduce HDV to undetectable levels. The outcomes of ECLIPSE 2 will be presented in the future, pending the completion of the trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250731294819) on July 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-31 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. has announced the initiation of the ECLIPSE 2 Phase 3 clinical trial, part of its global ECLIPSE registrational program for chronic hepatitis delta <a href=\"https://laohu8.com/S/CHD\">$(CHD)$</a>. The trial aims to evaluate the efficacy of combining tobevibart and elebsiran against continued bulevirtide monotherapy in patients with CHD who have not achieved undetectable levels of hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> RNA despite ongoing treatment with bulevirtide. ECLIPSE 2 is one of three trials in the program, designed to provide the necessary efficacy and safety data for potential submission to global regulatory agencies. This development follows compelling results from the Phase 2 SOLSTICE clinical trial, which demonstrated the potential of the investigational combination to reduce HDV to undetectable levels. The outcomes of ECLIPSE 2 will be presented in the future, pending the completion of the trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250731294819) on July 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDLtr9Rl:1","article_id":"2555838315","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555838315","pubTimestamp":1753963543,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vir Biotechnology Inc. has announced the initiation of the ECLIPSE 2 Phase 3 clinical trial, part of its global ECLIPSE registrational program for chronic hepatitis delta . The trial aims to evaluate the efficacy of combining tobevibart and elebsiran against continued bulevirtide monotherapy in patients with CHD who have not achieved undetectable levels of hepatitis delta virus  RNA despite ongoing treatment with bulevirtide. ECLIPSE 2 is one of three trials in the program, designed to provide the necessary efficacy and safety data for potential submission to global regulatory agencies. This development follows compelling results from the Phase 2 SOLSTICE clinical trial, which demonstrated the potential of the investigational combination to reduce HDV to undetectable levels. The outcomes of ECLIPSE 2 will be presented in the future, pending the completion of the trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","VIR":"Vir Biotechnology, Inc.","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓","BK4139":"生物科技"},"translate_title":"Vir Biotechnology启动慢性δ型肝炎治疗3期ECLIPSE 2试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":0.9},"content_text":"Vir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment\n    \n\n        Vir Biotechnology Inc. has announced the initiation of the ECLIPSE 2 Phase 3 clinical trial, part of its global ECLIPSE registrational program for chronic hepatitis delta $(CHD)$. The trial aims to evaluate the efficacy of combining tobevibart and elebsiran against continued bulevirtide monotherapy in patients with CHD who have not achieved undetectable levels of hepatitis delta virus $(HDV)$ RNA despite ongoing treatment with bulevirtide. ECLIPSE 2 is one of three trials in the program, designed to provide the necessary efficacy and safety data for potential submission to global regulatory agencies. This development follows compelling results from the Phase 2 SOLSTICE clinical trial, which demonstrated the potential of the investigational combination to reduce HDV to undetectable levels. The outcomes of ECLIPSE 2 will be presented in the future, pending the completion of the trial.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250731294819) on July 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}